# T2 Biosystems (TTOO) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/TTOO
## Company Profile
- Ticker: TTOO
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States
- Tags: Diagnostics
## Stock Data
- Close: 0.001 USD
- Market cap: Not available USD
- Last updated: 2026-09-03
## Business Overview
T2 Biosystems is a medical diagnostics company focused on rapid pathogen detection and bloodstream infection testing. Its business is centered on delivering fast diagnostic information to clinical settings.
## Why The Stock Is Moving

As of Sep 3, 2026, TTOO closed up 150.0% at $0.0010. No new same-company headline was identified in the current news window.

## Geographic Base

T2 Biosystems is headquartered in the United States and listed on NASDAQ. It sits in medical diagnostics rather than biotechnology therapeutics.

## Business Model

The company depends on test adoption, hospital utilization, and commercialization execution in a challenging diagnostics market. Investors usually watch sales, reimbursement, and operating discipline.

## Landscape Position

T2 Biosystems belongs to the diagnostics infrastructure layer of healthcare. It is not a drug developer, but it matters to clinical workflow because rapid testing can change treatment decisions.

## Future Catalysts

- T2 Biosystems is a legacy / closeout story now, with catalysts limited to any strategic or asset-resolution update. There is no active standalone growth story left.

## Recent News
- 2025-01-07 14:00 EST — [T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results](https://biopharmsignal.com/news/TTOO/t2-biosystems-announces-preliminary-fourth-quarter-and-full-year-2024-financial-results) — Source: T2 Biosystems
- 2024-12-18 14:00 EST — [T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor](https://biopharmsignal.com/news/TTOO/t2-biosystems-announces-sale-of-four-t2dx-instruments-to-existing-european-distributor) — Source: T2 Biosystems
- 2024-12-17 14:00 EST — [T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally](https://biopharmsignal.com/news/TTOO/t2-biosystems-achieves-key-milestone-with-250-000th-novel-sepsis-test-shipped-globally) — Source: T2 Biosystems
- 2024-12-16 14:00 EST — [T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.](https://biopharmsignal.com/news/TTOO/t2-biosystems-announces-extension-of-multi-year-capital-equipment-supplier-agreement-with-vizient-inc) — Source: T2 Biosystems
- 2024-12-09 14:00 EST — [T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens](https://biopharmsignal.com/news/TTOO/t2-biosystems-announces-plans-to-license-its-proprietary-technology-to-expand-its-leadership-in-direct-from-whole-blood-detection-of-sepsis-causing-pathogens) — Source: T2 Biosystems